Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IRE + γδ T cells is a combination therapy approach being investigated at Fuda Cancer Hospital in Guangzhou, China, for the treatment of locally advanced pancreatic cancer. The therapy combines Irreversible Electroporation (IRE), a non-thermal ablation technique that uses electrical pulses to induce tumor cell death, with allogeneic gamma-delta (γδ) T cell immunotherapy. IRE is a physical ablation procedure that delivers short, high-voltage electrical pulses to create nanoscale defects (nanopores) in cell membranes, inducing apoptosis without damaging surrounding structures like blood vessels and nerves. The γδ T cells represent a subset of T lymphocytes that are administered as an immunotherapy component to provide direct cytotoxic anti-tumor activity and stimulate a broader immune response. This procedural-biologic combination aims to reduce local tumor burden while simultaneously targeting residual or metastatic disease through immune activation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IRE + γδ T cells.